Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04586244
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Italy
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04463771
- Locations
- 🇺🇸
Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Alain Algazi
- Registration Number
- NCT04231864
Pembrolizumab-Epacadostat Combination to Treat Muscle-invasive Bladder UrotheLIAl canceR: PECULIAR Study
- Conditions
- Interventions
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Chase Heaton, MD
- Target Recruit Count
- 14
- Registration Number
- NCT03823131
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03602586
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Grant Medical Center, Columbus, Ohio, United States
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT03592407
- Locations
- 🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope West Covina, West Covina, California, United States
INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT03589651
- Locations
- 🇺🇸
Rutgers Cancer Institute of Nj, New Brunswick, New Jersey, United States
🇺🇸Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT03532295
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 49
- Registration Number
- NCT03516708
- Locations
- 🇺🇸
University of California Irvine - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.